Seroprevalence of SARS-CoV-2 IgG in healthcare workers and other staff at North Bristol NHS Trust: a sociodemographic analysis - Jones, Christopher R.; Hamilton, Fergus W.; Thompson, Ameeka; Morris, Tim T.; Moran, Ed (medRxiv, 2020)
Background Healthcare workers (HCWs) are at increased risk of infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There are limited data exploring the relative impact of geographical and socioeconomic factors on risk of SARS-CoV-2 infection among HCWs.Aim To estimate and explore SARS-CoV-2 IgG antibody seroprevalence in HCWs and support staff at a hospital in South West England.Methods We conducted a nested cross-sectional study from May-July 2020. Inverse probability weighted regression was used to estimate seroprevalence of SARS-CoV-2 and associations with demographic and socioeconomic risk factors that were robust to selection into testing.Findings Attendance for testing varied by demographic and socioeconomic factors. The overall rate of SARS-CoV-2 IgG seroprevalence among tested staff was 9.3% (638/6858). The highest seroprevalence was found in wards associated with SARS-CoV-2 outbreaks and among junior staff with patient-facing roles. Black, Asian and Minority Ethnic (BAME) staff had increased odds of SARS-CoV-2 seroprevalence (adjusted OR: 1.99, 95%CI: 1.69, 2.34; p<0.001) relative to White staff, except for those categorised as Medical/Dental. We found a significant association between neighbourhood deprivation and seroprevalence (p<0.01). Seroprevalence ranged from 12% in staff residing in areas with the greatest relative deprivation to 8.4% in the least deprived.Conclusion Transmission between staff groups is evident within the healthcare setting. BAME individuals were at increased risk of infection with SARS-CoV-2. Work role, area of residence, and neighbourhood deprivation all contribute to SARS-CoV-2 infection risk. As hospitals introduce routine staff SARS-CoV-2 testing they should consider differential uptake of testing among staff groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was granted by the North West - Greater Manchester West Research Ethics Committee (20/NW/0354). Data were processed under the COVID-19 Control of Patient Information (COPI) arrangements (see https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-controllers-to-share-information). All procedures were conducted in line with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materials.